Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880205 | 1.00 | ALOX5 (0.44) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL9880202 | 0.98 | ALOX5 (0.45) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL9880204 | 0.98 | ALOX5 (0.45) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL21538195 | 0.93 | ALOX5 (0.35) | ALOX5APPPTPN1NR1H4 | |
| SCHEMBL13746651 | 0.92 | APP (0.35) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29725739 | 0.91 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL29406557 | 0.91 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL23940981 | 0.90 | ALOX5 (0.40) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL9882380 | 0.90 | ALOX5 (0.40) | ALOX5APPPTPN1NR1H4BACE1 | |
| SCHEMBL22863234 | 0.90 | ALOX5 (0.36) | ALOX5APPPTPN1NR1H4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49351-E1 | Cytoprotective agent | BIOGEN MA INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-RE47684-E1 | Cytoprotective agent | TMS CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| US-9078880-B2 | Cytoprotective agent | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9078880-B2 | Cytoprotective agent | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20120135996-A1 | CYTOPROTECTIVE AGENT | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2012-05-31 | — | — | US | disclosed |
| US-20120135996-A1 | CYTOPROTECTIVE AGENT | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135996-A1 | CYTOPROTECTIVE AGENT | TXN2, TXNRD2, AIFM1 | ALOX5 700/4885APP 2506/4885PTPN1 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.